irinotecan has been researched along with Uremia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furukubo, T; Hojyo, A; Izumi, S; Kambara, K; Katsube, Y; Koide, H; Minegaki, T; Nishiguchi, K; Ochiai, M; Ogawa, K; Shima, D; Torii, N; Tsujimoto, M; Yamakawa, T | 1 |
| Furukubo, T; Hojo, A; Izumi, S; Katsube, Y; Koide, H; Minegaki, T; Nishiguchi, K; Ochiai, M; Shima, D; Tsujimoto, M; Yamakawa, T | 1 |
2 other study(ies) available for irinotecan and Uremia
| Article | Year |
|---|---|
Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.
Topics: Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Half-Life; HEK293 Cells; Humans; Irinotecan; Kidney Failure, Chronic; Liver; Liver-Specific Organic Anion Transporter 1; Renal Dialysis; Serum Albumin; Toxins, Biological; Uremia | 2017 |
Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease.
Topics: Carboxylesterase; Case-Control Studies; Fatty Acids; Humans; Irinotecan; Kidney Failure, Chronic; Microsomes, Liver; Nitrophenols; Topoisomerase I Inhibitors; Uremia | 2018 |